COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Single-arm, Open-label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 and ALLO-647 to Evaluate an Anti-BMCA Allogeneic CAR T Cell Therapy with or without Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma

Protocol No
ALLOGENE-ALLO-715-101-RRMM
Principal Investigator
Parameswaran Hari
Phase
I
Summary
To test the safety of ALLO-715 in combination with ALLO-647 and to determine the safe dose of ALLO-715 following lymphodepletion with ALLO-647.
Description
Phase 1 Study of ALLO-715, an antiBCMA Allo CAR-T cell therapy for pt with rrMM
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL